An independent cohort of 20 NSCLC patients with c-Met positivity with or without MET amplification (11 and 9, respectively) who were treated with the c-Meti crizotinib or capmatinib was selected (Supplementary Table S6). This evidence concerns the gene MET and non-small cell lung carcinoma.